Royalty Pharma Sub-Manager, LLC
CIK: 2081668
Increased
0
Decreased
0
Holdings (4)
Q2 2026 13F, quarter ended Jun 30, 2026, filed Aug 14, 2026
- CYTK
CYTOKINETICS, INC
$83.52M
980,392 sh34.52%+0.0% - ZBIO
ZENAS BIOPHARMA, INC.
$60.61M
2.39M sh25.05%+0.0% - KLRA
KAILERA THERAPEUTICS
$54.09M
2.46M sh22.36%New - BHVN
BIOHAVEN LTD
$43.7M
2.94M sh18.06%+0.0%
| Security | Shares | Value | Change | Weight | Period |
|---|---|---|---|---|---|
 CYTK CYTOKINETICS, INC | 980,392 | $83.52M | +0.0% | 34.52% | Q2 2026 |
 ZBIO ZENAS BIOPHARMA, INC. | 2.39M | $60.61M | +0.0% | 25.05% | Q2 2026 |
 KLRA KAILERA THERAPEUTICS | 2.46M | $54.09M | New | 22.36% | Q2 2026 |
 BHVN BIOHAVEN LTD | 2.94M | $43.7M | +0.0% | 18.06% | Q2 2026 |
1-4 of 4 holdings
Sector Allocation
SEC Filings
| Form | Description | Filed |
|---|---|---|
About Royalty Pharma Sub-Manager, LLC
Royalty Pharma Sub-Manager, LLC is an Investment Adviser that reports its US-listed stock and option positions to the SEC on Form 13F (CIK 2081668). Signal8 holds 30 13F filings from it. Its SEC filings list New York as its state of incorporation.
Its most recent 13F holdings report covers Q2 2026 (the quarter ended Jun 30, 2026) and was filed on Aug 14, 2026. That report lists 4 securities, not counting options, the same number as in Q1 2026.
Its four largest reported positions, in order, are CYTOKINETICS, INC (CYTK), ZENAS BIOPHARMA, INC. (ZBIO), KAILERA THERAPEUTICS (KLRA) and BIOHAVEN LTD (BHVN).
Recent 13F filings by Royalty Pharma Sub-Manager, LLC
- Q2 2026: 13F-HR/A filed Aug 21, 2026, listing 4 securities.
- Q2 2026: 13F-HR filed Aug 14, 2026, listing 4 securities.
- Q1 2026: 13F-HR/A filed Aug 21, 2026, listing 4 securities.
- Q1 2026: 13F-HR filed May 14, 2026, listing 4 securities.
- Q4 2025: 13F-HR/A filed Aug 21, 2026, listing 4 securities.
- Q4 2025: 13F-HR filed Mar 31, 2026, listing 4 securities.